Data quality challenges in systemic lupus erythematosus trials: How can this be optimized?

Current Rheumatology Reports

Volumn 14, Issue 4, 2012, Pages 324-333

  Pike, Marilyn C ^a   Kelley, Lexy ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ReSearch Pharmaceutical Services   (United States)

Author keywords

Central adjudication committees; Challenge; Data quality; Disease Activity Index; New agents; Optimize; SLE; Systemic lupus erythematosus; Therapy; Trials

Indexed keywords

PEXELIZUMAB; TIOTROPIUM BROMIDE;

ACUTE HEART INFARCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT ASSESSMENT; PROCESS DEVELOPMENT; QUALITY CONTROL; SCREENING TEST; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 84864862803     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0261-7     Document Type: Article

References (57)

1. Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am. 1995;21:81.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine. 2003;82:299.
3. Panopalis P, Clarke AC. Systemic Lupus Eryhtematosus: clinical manifestations, treatment and economics. Expert Rev Pharmacoe-conomics Outcomes Res. 2006;6:563-75.
4. Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: new advances in targeted therapies. Ann N Y Acad Sci. published online. 2012;1247:138-152.
5. Schur PH, Wallace DJ. Overview of the therapy and prognosis of systemic lupus erythematosus in adults. UptoDate. http://www. uptodate.com (accessed February 2012).
6. Aberer E. Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus. Lupus. 2010;19:1118-24.
7. Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology. 2009;48:281-4.
8. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69:964.
9. Meng T, Weber MS, Hemmer B. Disease modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68:2445-68.
10. D' Haens G, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose and how to predict response? Am J Gastroenterol. 2011;106:199-212.
11. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644.
12. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19:53-9.
13. Bombardier C, Gladman DD, Urowicz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-40.
14. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8:685-91.
15. Buyon J, Petri M, Kim M. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Int Med. 2005;142:953-62.
16. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.
17. Tourma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 2010;19:49-50.
18. Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus. 2008;17:91.
19. Isenberg DA, Gordon C, BILAG Group. British Isles Lupus Assessment Group. From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus. 2000;9:651-4.
20. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447-58.
21. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2004;2005(44):902-6.
22. Yee CS, Farewell V, Isenberg D, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology. 2009;48:691-5.
23. Fitzgerald JD, Grossman JM, Kalunian KC. Annual systemic lupus erythematosus are rates in university practice abstract. Arthritis Rheum. 1998;41(9 Suppl):S219.
24. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM™, a phase IIb study. Arthritis Rheum. 2010;62 (Suppl S10):S1452.
25. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-9.
26. Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology. Advance Access published November 21, 2011:1-8.
27. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066-73.
28. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260-3.
29. FDA briefing information, belimumab (BENLYSTA), for the November 16, 2010 meeting of the Arthritis Advisory Committee. www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/ucm233578.htm (Accessed on November 16, 2010).
30. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143-51.
31. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30.
32. Navarra SV, Guzman RM, Gallacher AE. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31.
33. Kalunian KC, Petri MA, Wallace DJ. BILAG-Measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM™. Arthritis Rheum. 2010;62(Suppl S10):S453.
34. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12: R204.
35. Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Brit J Clin Pharm. 2011;71:175-82.
36. Wallace D, Strand V, Furie R, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint. Arthritis Rheum. 63(Suppl):S885.
37. Petri MA, Pike MC, Kelley L, et al. Systemic lupus erythematosus responder index assessment of responders in EMBLEM, a phase IIb study in patients with moderate to severe systemic lupus erythematosus. Arthritis Rheum. 2011;63(Suppl):S885.
38. Sridharan S, Zhou T, Immermann F, et al. Low placebo responses and clinical components of the biomarkers of lupus disease (BOLD) study may provide useful insights for systemic lupus erythematosus clinical trial design. Arthritis Rheum. 2011;63(Suppl):S543.
39. FDA guidance for clinical trial sponsors: Establishment and operation of clinical trial data monitoring committees. http://www.fda. gov/downloads/ RegulatoryInformation/Guidances/ucm127073. pdf (Accessed February 8, 2012).
40. Kradjian S, Gutheil J, Baratelle AM, et al. Development of a charter for an endpoint assessment and adjudication committee. Drug Inf J. 2005;39:53-61.
41. Tyner CA, Somaratne R, Cabell CH, et al. Quintiles white paper executive summary: establishment and operation of clinical endpoint committees: best practice for implementation across the biopharma-ceutical industry. http://www.quintiles.com/information-library/white-papers/clinical-endpoint- committees (Accessed February 8, 2012).
42. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med. 2001;2:180-6.
43. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction end-points in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med. 2001;2:187-94.
44. Mahaffey KW, Wampole JL, Stebbins A, et al. Strategic lessons from the clinical event classification process for the assessment of pexelizumab in acute myocardial infarction (APEX-AMI) trial. Contemp Clin Trials. 2011;32:178-87.
45. McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Resp. Med. Advance Access. 2011, doi:10.1016/j. rmed.2011.10.009.
46. Amit O, Bushnell W, Dodd L, et al. Blinded independent central review of the progression-free survival endpoint. Oncologist. 2010;15:492-5.
47. FDA Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. May 2007, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (Accessed February 8, 2012).
48. FDA Guidance for Industry: Systemic lupus erythematosus-Developing medical products for treatment. June 2010, http://www.elsevierbi.com/~/media/ Images/Publications/Archive/The% 20Pink%20Sheet%20Daily/2010/9/14/14100914002/ 0621-sle- guidance.pdf (Accessed February 8, 2010). This is the regulatory guidance for designing SLE trials.
49. Schur PH, Khoshbin S. Neurologic manifestations of systemic lupus erythematosus. Disclosures: Last literature review version 19.2: May 2011. (This topic last updated: February 18, 2011).
50. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology. 2002;41:605.
51. Omdal R, Henriksen OA, Mellgren SI, Husby G. Peripheral neuropathy in systemic lupus erythematosus. Neurology. 1991;41:808.
52. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127:1200.
53. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index. Arch Dermatol. 2008;144:173-80.
54. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-806.
55. Wachtel TL, Berry CC, Wachtel EE, Frank HA. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-70.
56. Lillegraven S, Prince FHM, Shadick NA, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
57. Touma Z, Urowitz MB, Fortin PR, et al. Systemic lupus erythe-matosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. J Rheumatol. 2011;38:868-73.